BVS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
BVS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-05-13), Bioventus's share price is $5.40. Bioventus's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2024 was $0.11. Hence, Bioventus's Price-to-Operating-Cash-Flow Ratio for today is 49.09.
The historical rank and industry rank for Bioventus's Price-to-Operating-Cash-Flow or its related term are showing as below:
During the past 9 years, Bioventus's highest Price-to-Operating-Cash-Flow Ratio was 52.49. The lowest was 6.03. And the median was 18.48.
Bioventus's Cash Flow from Operations per share for the three months ended in Mar. 2024 was $-0.10. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2024 was $0.11.
During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Bioventus was -32.10% per year. During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -49.50% per year.
During the past 9 years, Bioventus's highest 3-Year average Operating Cash Flow per Share Growth Rate was 154.90% per year. The lowest was -49.50% per year. And the median was 39.10% per year.
The historical data trend for Bioventus's Price-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bioventus Annual Data | |||||||||||||||||||
Trend | Dec13 | Dec14 | Dec15 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||||||
Price-to-Operating-Cash-Flow | Get a 7-Day Free Trial | - | - | 37.54 | - | 21.51 |
Bioventus Quarterly Data | ||||||||||||||||||||
Dec18 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Price-to-Operating-Cash-Flow | Get a 7-Day Free Trial | 6.60 | 10.07 | 19.88 | 21.51 | 47.27 |
For the Medical Devices subindustry, Bioventus's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Bioventus's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Bioventus's Price-to-Operating-Cash-Flow falls into.
Bioventus's Price-to-Operating-Cash-Flow ratio for today is calculated as
Price-to-Operating-Cash-Flow Ratio | = | Share Price | / | Cash Flow from Operations per share (TTM) |
= | 5.40 | / | 0.11 | |
= | 49.09 |
Bioventus's Share Price of today is $5.40.
Bioventus's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.11.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).
It can also be calculated from the numbers for the whole company:
Price-to-Operating-Cash-Flow Ratio | = | Market Cap | / | Cash Flow from Operations |
Thank you for viewing the detailed overview of Bioventus's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Bihl Anthony P Iii | director, officer: Interim CEO | 807 SMITH RIDGE ROAD, NEW CANAAN CT 06840 |
John A. Bartholdson | director, 10 percent owner | C/O STONINGTON PARTNERS, INC., 540 MADISON AVENUE, 25TH FLOOR, NEW YORK NY 10022 |
Juniper Investment Company, Llc | 10 percent owner | 555 MADISON AVENUE, 24TH FLOOR, NEW YORK NY 10022-3315 |
Katrina J Church | officer: SVP & Chief Compliance Officer | 3290 WEST BAYSHORE ROAD, PALO ALTO CA 94303 |
Alexis P Michas | 10 percent owner | 940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451 |
Juniper Targeted Opportunities, Lp | 10 percent owner | 555 MADISON AVENUE, 24TH FL, NEW YORK NY 10022 |
Juniper Targeted Opportunity Fund, L.p. | 10 percent owner | 555 MADISON AVENUE, 24TH FLOOR, NEW YORK NY 10022 |
William A Hawkins | director | MEDTRONIC INC, 710 MEDTRONIC PKWY, MS LC310, MINNEAPOLIS MN 55432-5604 |
Mark Leonard Singleton | officer: SEE REMARKS | C/O BIOVENTUS INC., 4721 EMPEROR BOULEVARD, SUITE 100, DURHAM NC 27703 |
Anthony D'adamio | officer: SVP & General Counsel | C/O BIOVENTUS INC., 4721 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703 |
Kenneth Michael Reali | director, officer: Chief Executive Officer | 5213 ATHERTON BRIDGE ROAD, RALEIGH NC 27613 |
John Nosenzo | officer: Chief Commercial Officer | C/O BIOVENTUS INC., 4721 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703 |
Alessandra Pavesio | officer: SVP & Chief Science Officer | C/O BIOVENTUS INC., 4721 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703 |
Gregory O. Anglum | officer: SVP and CFO | C/O BIOVENTUS INC., 4721 EMPEROR BOULEVARD, SUITE 100, DURHAM NC 27703 |
Michelle Mcmurry-heath | director | C/O BIOVENTUS INC., 4721 EMPEROR BOULEVARD, SUITE 100, DURHAM NC 27703 |
From GuruFocus
By Marketwired • 09-20-2023
By Marketwired • 08-01-2023
By sperokesalga sperokesalga • 02-28-2023
By sperokesalga sperokesalga • 03-02-2023
By sperokesalga sperokesalga • 03-29-2023
By sperokesalga sperokesalga • 05-15-2023
By GuruFocus Research • 08-16-2023
By Marketwired • 10-31-2023
By sperokesalga sperokesalga • 05-10-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.